News

Celltrion Enhances Access to STEQEYMA® Through Costco Program

Celltrion Enhances Access to STEQEYMA® Through Costco Program

Celltrion Introduces STEQEYMA® to Costco Members

Celltrion's STEQEYMA® (ustekinumab-stba) has been welcomed into the Costco Member Prescription Program, marking a significant milestone for patients seeking access to essential treatments. This biosimilar is a generic form of STELARA® (ustekinumab) and is designed to improve affordability and accessibility for individuals with inflammatory conditions.

Commitment to Accessibility in Healthcare

Francine Galante, Vice President of Market Access at Celltrion USA, expressed the company's dedication to enhancing patient care by reducing financial barriers associated with high-cost medications. She noted, "The addition of STEQEYMA to the Costco Member Prescription Program, alongside adalimumab-aaty, reaffirms our commitment to accessibility for critical treatments. This partnership enables us to help patients more easily afford the medications they need to manage their health effectively."

About STEQEYMA

STEQEYMA is available as both a subcutaneous injection and an intravenous infusion. It is indicated for the treatment of various conditions including plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), and ulcerative colitis (UC). This broad range of use makes STEQEYMA an essential option for many patients, particularly those affected by serious autoimmune ailments.

The Costco Member Prescription Program Explained

The Costco Member Prescription Program serves as a vital resource, offering discounted prescription prices for eligible members and their dependents. Available at Costco Specialty Pharmacies and participating locations, the program allows individuals to access STEQEYMA at a lower cost, especially beneficial for those who may be uninsured or face challenges with their insurance coverage.

Future Availability and Plans

As per the announcements, STEQEYMA will be accessible in the U.S. starting April 1 for members who wish to purchase their prescriptions with cash or are part of self-funded employer plans. This timing adds an exciting dynamic for patients eagerly awaiting affordable options for their treatments.

Safety and Important Information

While STEQEYMA is effective for many patients, it is crucial for healthcare providers and patients alike to be aware of the safety information associated with the drug. Known contraindications include significant hypersensitivity to ustekinumab products. Serious infections may occur, thus beginning treatment during an active infection is not advisable. Care should be taken with tuberculosis evaluations and patients should be monitored for potential malignancy and severe allergic reactions.

For More Information

Detailed safety information, indications, and adverse reactions associated with STEQEYMA are essential for informed treatment decisions. Healthcare practitioners should guide patients through this information to ensure a safe treatment journey. The subcutaneous injection comes in effective dosages, helping promote better treatment adherence.

About Celltrion and Its Innovations

Celltrion, a leading biopharmaceutical company, specializes in developing and manufacturing innovative therapeutics that actively improve health outcomes worldwide. With a strong focus on the biosimilar sector, Celltrion was among the first in the industry to achieve success with monoclonal antibody biosimilars. Their diverse pharmaceutical portfolio includes important therapeutic areas such as immunology and oncology.

Celltrion USA's Commitment

Established in 2018, Celltrion USA is dedicated to improving the accessibility of high-quality biologics for patients within the country. With ten biosimilars currently approved by the U.S. FDA and a commitment to ongoing innovation, the company continuously strives to meet the needs of patients through its extensive research and development efforts.

Frequently Asked Questions

What is STEQEYMA®?

STEQEYMA (ustekinumab-stba) is a biosimilar to STELARA® and is used to treat various inflammatory diseases.

How can I access STEQEYMA through Costco?

Eligible Costco members can obtain STEQEYMA at a reduced cost via the Costco Member Prescription Program at participating pharmacies.

What conditions does STEQEYMA treat?

STEQEYMA is indicated for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

When will STEQEYMA be available?

STEQEYMA will be available starting April 1 for specific plans and cash-paying patients in the U.S.

What should I know about the safety of STEQEYMA?

Patients must discuss potential contraindications and side effects with a healthcare provider before starting treatment with STEQEYMA.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 38

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 60

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 17

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

INTCO Medical Surges Ahead with 40.6% Revenue Boost

Updated Category News Views 94

Eying Growth: INTCO Medical's Impressive Revenue Surge In today's corporate world, a 40.6% revenue jump over a single half-year isn't something to sneeze at. INTCO Medical, a heavyweight in the disposable glove industry, has done exactly that. The whispers out of Zibo, China, hint at a company that’s firing on all cylinders with $1.03 billion in their pockets for the...

Continue Reading
Taylor Davis Joins Pivot Point Consulting to Boost Client Success

Updated Category News Views 108

Pivot Point Consulting brought in a big player back then: Taylor Davis, the former President of KLAS Research. He wasn't just some guy; he founded the KLAS Arch Collaborative. This move was about shaking things up in healthcare consulting during tough times. Desks were buzzing over this power shift. In his past gig at KLAS, Davis was instrumental in creating standards...

Continue Reading
Entegris' Financial Highlights and Outlook for 2025

Updated Category News Views 971

Entegris Reports Strong Fourth Quarter Performance Entegris, Inc. (NASDAQ: ENTG) has recently released its financial results marking a robust conclusion to the fiscal year. The company's fourth-quarter performance surpassed projections for both revenue and non-GAAP earnings per share. CEO Insights on Market Dynamics Bertrand Loy, the President and CEO of Entegris,...

Continue Reading
Top Dividend Stocks Insiders Increased Their Investments In January

Updated Category News Views 109

Insider Purchasing Trends in Dividend Stocks January unveiled strong insider buying activity across various dividend-paying stocks, pointing to confidence in future growth. Leaders in this buying spree were notable companies including Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). Such movements may indicate these stocks are worth...

Continue Reading
FDA Approves Omvoh for Crohn's Disease: A New Era in Treatment

Updated Category News Views 515

FDA Approves Omvoh for Crohn's Disease Eli Lilly and Company (NYSE: LLY) proudly announces the FDA's approval of Omvoh (mirikizumab-mrkz), a groundbreaking treatment for adults suffering from moderately to severely active Crohn's disease. This marks a significant advancement, as Omvoh is now recognized for treating not just this debilitating condition but also ulcerative...

Continue Reading